ntravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity

作     者：Xiu-Juan Li Xiao-Peng Yang Shuang Sun Xiao-Bei Lyu Heng Jia Li Xiu-Juan;Yang Xiao-Peng;Sun Shuang;Lyu Xiao-Bei;Jia Heng

作者机构：Department of Ophthalmology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China Department of Medical Equipment The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China Department of Ophthalmology Children's Hospital of Zhengzhou Zhengzhou Henan 450052 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2016年第129卷第23期

页      面：2879-2881页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：supported by grants from the Projects of Henan Health and Family Planning Commission Henan Health Department Henan Science and Technology Department 

主　　题：Aggressive Posterior Retinopathy of Prematurity Intravitreal Injection Ranibizumab 

摘      要：Retinopathy ofprematurity （ROP） is a proliferative disease that affects infants of young gestational age （GA） and low birth weight （BW）. Aggressive posterior ROP （AP-ROP） is a rapidly progressing and severe presentation of ROP. It is characterized as posterior location （zone 1 or posterior zone I1）, Stage 3, and with plus disease （arterial tortuosity and venous dilation）. It can quickly lead to retinal detachment and blindness if not treated in time.